6128 results
Cited 37 times since 2018 (5.9 per year)
source: EuropePMC
JACC. Cardiovascular imaging,
Volume 12, Issue 1, 15 3 2018, Pages 135-145
Transcatheter Aortic Heart Valves: Histological Analysis Providing Insight to Leaflet Thickening and Structural Valve Degeneration.
Sellers SL, Turner CT, Sathananthan J, Cartlidge TRG, Sin F, Bouchareb R, Mooney J, Nørgaard BL, Bax JJ, Bernatchez PN, Dweck MR, Granville DJ, Newby DE, Lauck S, Webb JG, Payne GW, Pibarot P, Blanke P, Seidman MA, Leipsic JA
Objectives: This study investigated processes causing leaflet thickening and structural valve degeneration (SVD). Background: Although transcatheter aortic valve replacement (TAVR) has changed the treatment of aortic stenosis, concerns remain regarding SVD, potentially related to valve thrombosis and thickening, based on studies using computed tomography (CT). Detailed histological analyses are provided to help attain insights into these processes. Methods: Explanted transcatheter heart valves (...
Abstract
Cited 6 times since 2018 (1 per year)
source: Scopus
JACC. Cardiovascular imaging,
Volume 12, Issue 1, 15 3 2018, Pages 216-217
Prognostic Value of Thoracic Aorta Calcification Burden in Patients Treated With TAVR.
Gegenava T, Vollema EM, Abou R, Goedemans L, van Rosendael A, van der Kley F, de Weger A, Ajmone Marsan N, Bax JJ, Delgado V
Abstract
Cited 19 times since 2018 (3 per year)
source: EuropePMC
European journal of human genetics : EJHG,
Volume 27, Issue 3, 12 2 2018, Pages 422-431
Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile.
Blauw LL, Noordam R, Soidinsalo S, Blauw CA, Li-Gao R, de Mutsert R, Berbée JFP, Wang Y, van Heemst D, Rosendaal FR, Jukema JW, Mook-Kanamori DO, Würtz P, Willems van Dijk K, Rensen PCN
According to the current dogma, cholesteryl ester transfer protein (CETP) decreases high-density lipoprotein (HDL)-cholesterol (C) and increases low-density lipoprotein (LDL)-C. However, detailed insight into the effects of CETP on lipoprotein subclasses is lacking. Therefore, we used a Mendelian randomization approach based on a genetic score for serum CETP concentration (rs247616, rs12720922 and rs1968905) to estimate causal effects per unit (µg/mL) increase in CETP on 159 standardized metabol...
Abstract
Cited 51 times since 2018 (8.1 per year)
source: EuropePMC
Journal of the American College of Cardiology,
Volume 73, Issue 4, 11 2 2018, Pages 387-396
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG, ODYSSEY OUTCOMES Committees and Investigators
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. Objectives: This pre-specified analysis determined the extent to which alirocuma...
Abstract
Cited 16 times since 2018 (2.5 per year)
source: EuropePMC
Heart (British Cardiac Society),
Volume 105, Issue 10, 10 2 2018, Pages 790-796
Long-term outcome after atrial correction for transposition of the great arteries.
Couperus LE, Vliegen HW, Zandstra TE, Kiès P, Jongbloed MRM, Holman ER, Zeppenfeld K, Hazekamp MG, Schalij MJ, Scherptong RWC
Objective: This study assessed adult survival and morbidity patterns in patients who underwent atrial correction according to Mustard or Senning for transposition of the great arteries (TGA). Methods: In 76 adult patients with TGA (59% male) after atrial correction, long-term survival and morbidity were investigated in three periods: early (30 years postoperatively). Results: The Mustard technique was performed in 41 (54%) patients, and the Senning technique was performed in 35 (46%) patients ag...
Abstract
Cited 10 times since 2018 (1.6 per year)
source: EuropePMC
Langenbeck's archives of surgery,
Volume 403, Issue 8, 10 2 2018, Pages 999-1005
Safety and efficacy of subtotal or total parathyroidectomy for patients with secondary or tertiary hyperparathyroidism in four academic centers in the Netherlands.
van der Plas WY, Dulfer RR, Koh EY, Vogt L, Appelman-Dijkstra NM, Schepers A, Rotmans JI, Pol RA, van Ginhoven TM, Hoorn EJ, Nieveen van Dijkum EJM, Engelsman AF, de Borst MH, Kruijff S, Dutch Hyperparathyroidism Study Group (DHSG)
Purpose: Hyperparathyroidism (HPT) is a common abnormality in patients with end-stage renal disease (ESRD). Since the introduction of cinacalcet in 2004, a shift from surgery toward predominantly medical treatment has occurred. Surgery is thought to be associated with more complications than oral medication. The aim of this retrospective study was to evaluate 30-day outcomes and effectiveness of parathyroidectomy (PTx) in ESRD patients in the Netherlands. Methods: A national database containing...
Abstract
Cited 13 times since 2018 (2.1 per year)
source: EuropePMC
International journal of cardiology,
Volume 278, 10 2 2018, Pages 84-87
Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: Follow-up of a multicenter randomized controlled trial.
van Dissel AC, Winter MM, van der Bom T, Vliegen HW, van Dijk APJ, Pieper PG, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJM, Bouma BJ
Objectives: In the VAL-SERVE (Valsartan in Systemic Right Ventricle) trial, three-year valsartan treatment improved systemic ventricular function only in symptomatic patients with congenitally or with an atrial switch corrected transposition of the great arteries. The aim of the current study was to investigate the longer-term clinical outcomes after valsartan treatment. Methods: From 2006 to 2009, 88 adults were randomly allocated 1:1 to either valsartan or placebo for three consecutive years....
Abstract
Cited 3 times since 2018 (0.5 per year)
source: EuropePMC
Anatomical record (Hoboken, N.J. : 2007),
Volume 302, Issue 1, 9 2 2018, Pages 83-92
Disruption of RHOA-ROCK Signaling Results in Atrioventricular Block and Disturbed Development of the Putative Atrioventricular Node.
Kelder TP, Vicente-Steijn R, Poelmann RE, Schalij MJ, Deruiter MC, Jongbloed MRM, Gittenberger-de Groot AC
The RHOA-ROCK signaling pathway is involved in numerous developmental processes, including cell proliferation, differentiation and migration. RHOA is expressed in the atrioventricular node (AVN) and altered expression of RHOA results in atrioventricular (AV) conduction disorders in mice. The current study aims to detect functional AVN disorders after disturbing RHOA-ROCK signaling in chicken embryos. RHOA-ROCK signaling was inhibited chemically by using the Rho-kinase inhibitor compound Y-27632...
Abstract
Cited 1163 times since 2018 (183.8 per year)
source: EuropePMC
The New England journal of medicine,
Volume 379, Issue 22, 7 1 2018, Pages 2097-2107
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators
Background: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had a...
Abstract
Cited 3 times since 2018 (0.5 per year)
source: EuropePMC
Annals of surgery,
Volume 268, Issue 5, 1 1 2018, Pages 756-761
No Clinical Benefit of Intramuscular Delivery of Bone Marrow-derived Mononuclear Cells in Nonreconstructable Peripheral Arterial Disease: Results of a Phase-III Randomized-controlled Trial.
Lindeman JHN, Zwaginga JJ, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ, Fibbe WE, Hamming JF
Background and aims: Prospects for no-option, end-stage peripheral artery disease (PAD) patients remain poor. Although results from open and semiblinded studies fuel hope for cell-based strategies in no-option patients, so far conclusions from the available placebo-controlled studies are not supportive. With the intention to end the remaining controversy with regard to cell therapy for PAD we conducted a confirmatory, double-blinded randomized placebo-controlled phase 3 trial. Study design: This...
Abstract
Cited 212 times since 2018 (33.4 per year)
source: EuropePMC
American journal of human genetics,
Volume 103, Issue 5, 1 1 2018, Pages 691-706
Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders.
Ligthart S, Vaez A, Võsa U, Stathopoulou MG, de Vries PS, Prins BP, Van der Most PJ, Tanaka T, Naderi E, Rose LM, Wu Y, Karlsson R, Barbalic M, Lin H, Pool R, Zhu G, Macé A, Sidore C, Trompet S, Mangino M, Sabater-Lleal M, Kemp JP, Abbasi A, Kacprowski T, Verweij N, Smith AV, Huang T, Marzi C, Feitosa MF, Lohman KK, Kleber ME, Milaneschi Y, Mueller C, Huq M, Vlachopoulou E, Lyytikäinen LP, Oldmeadow C, Deelen J, Perola M, Zhao JH, Feenstra B, LifeLines Cohort Study, Amini M, CHARGE Inflammation Working Group, Lahti J, Schraut KE, Fornage M, Suktitipat B, Chen WM, Li X, Nutile T, Malerba G, Luan J, Bak T, Schork N, Del Greco M F, Thiering E, Mahajan A, Marioni RE, Mihailov E, Eriksson J, Ozel AB, Zhang W, Nethander M, Cheng YC, Aslibekyan S, Ang W, Gandin I, Yengo L, Portas L, Kooperberg C, Hofer E, Rajan KB, Schurmann C, den Hollander W, Ahluwalia TS, Zhao J, Draisma HHM, Ford I, Timpson N, Teumer A, Huang H, Wahl S, Liu Y, Huang J, Uh HW, Geller F, Joshi PK, Yanek LR, Trabetti E, Lehne B, Vozzi D, Verbanck M
C-reactive protein (CRP) is a sensitive biomarker of chronic low-grade inflammation and is associated with multiple complex diseases. The genetic determinants of chronic inflammation remain largely unknown, and the causal role of CRP in several clinical outcomes is debated. We performed two genome-wide association studies (GWASs), on HapMap and 1000 Genomes imputed data, of circulating amounts of CRP by using data from 88 studies comprising 204,402 European individuals. Additionally, we performe...
Abstract
Cited 107 times since 2018 (16.9 per year)
source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Volume 20, Issue 11, 1 1 2018, Pages 1719-1753
Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE.
Hernández-Madrid A, Paul T, Abrams D, Aziz PF, Blom NA, Chen J, Chessa M, Combes N, Dagres N, Diller G, Ernst S, Giamberti A, Hebe J, Janousek J, Kriebel T, Moltedo J, Moreno J, Peinado R, Pison L, Rosenthal E, Skinner JR, Zeppenfeld K, ESC Scientific Document Group
The population of patients with congenital heart disease (CHD) is continuously increasing with more and more patients reaching adulthood. A significant portion of these young adults will suffer from arrhythmias due to the underlying congenital heart defect itself or as a sequela of interventional or surgical treatment. The medical community will encounter an increasing challenge as even most of the individuals with complex congenital heart defects nowadays become young adults. Within the past 20...
Abstract
Interactive cardiovascular and thoracic surgery,
Volume 27, Issue 5, 1 1 2018, Pages 657-663
Prognostic value of left ventricular reverse remodelling and recurrent mitral regurgitation after personalized surgical treatment of patients with non-ischaemic cardiomyopathy and functional mitral regurgitation.
Petrus AHJ, Tops LF, Timmer E, Versteegh MIM, Dekkers OM, Klautz RJM, Braun J
Objectives: The aim of this study was to determine the prevalence of left ventricular reverse remodelling (LVRR) and recurrent mitral regurgitation (MR) at mid-term follow-up (1-2 years after surgery) in patients after personalized surgical treatment of heart failure and functional MR due to non-ischaemic cardiomyopathy and to assess their prognostic impact on long-term clinical outcomes. Methods: Consecutive patients with refractory heart failure and non-ischaemic MR, who underwent mitral valve...
Abstract
Cited 5 times since 2018 (0.8 per year)
source: EuropePMC
European heart journal. Cardiovascular Imaging,
Volume 19, Issue 11, 1 1 2018, Pages 1287-1293
Long-term prognostic value of single-photon emission computed tomography myocardial perfusion imaging after primary PCI for STEMI.
Smit JM, Hermans MP, Dimitriu-Leen AC, van Rosendael AR, Dibbets-Schneider P, de Geus-Oei LF, Mertens BJ, Schalij MJ, Bax JJ, Scholte AJ
Aims: The aim of this study was to determine the long-term prognostic value of infarct size and myocardial ischaemia on single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI) after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Methods and results: In total, 1092 STEMI patients who underwent primary PCI and SPECT MPI within 1-6 months were included (median follow-up time of 6.9 years). In the entire cohort, SP...
Abstract
Cited 123 times since 2018 (19.4 per year)
source: EuropePMC
European heart journal,
Volume 39, Issue 41, 1 1 2018, Pages 3701-3711
Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry.
Fairbairn TA, Nieman K, Akasaka T, Nørgaard BL, Berman DS, Raff G, Hurwitz-Koweek LM, Pontone G, Kawasaki T, Sand NP, Jensen JM, Amano T, Poon M, Øvrehus K, Sonck J, Rabbat M, Mullen S, De Bruyne B, Rogers C, Matsuo H, Bax JJ, Leipsic J, Patel MR
Aims: Non-invasive assessment of stable chest pain patients is a critical determinant of resource utilization and clinical outcomes. Increasingly coronary computed tomography angiography (CCTA) with selective CCTA-derived fractional flow reserve (FFRCT) is being used. The ADVANCE Registry, is a large prospective examination of using a CCTA and FFRCT diagnostic pathway in real-world settings, with the aim of determining the impact of this pathway on decision-making, downstream invasive coronary a...
Abstract
Cited 1220 times since 2018 (192.4 per year)
source: EuropePMC
Circulation,
Volume 138, Issue 20, 1 1 2018, Pages e618-e651
Fourth Universal Definition of Myocardial Infarction (2018).
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction
Abstract
Cited 89 times since 2018 (14 per year)
source: EuropePMC
JAMA cardiology,
Volume 3, Issue 11, 1 1 2018, Pages 1060-1068
Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics.
Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA, Chambers J, Rosenhek R, Habib G, Lloyd G, Nistri S, Garbi M, Marchetta S, Fattouch K, Coisne A, Montaigne D, Modine T, Davin L, Gach O, Radermecker M, Liu S, Gillam L, Rossi A, Galli E, Ilardi F, Tastet L, Capoulade R, Zilberszac R, Vollema EM, Delgado V, Cosyns B, Lafitte S, Bernard A, Pierard LA, Bax JJ, Pibarot P, Oury C
Importance: The natural history and the management of patients with asymptomatic aortic stenosis (AS) have not been fully examined in the current era. Objective: To determine the clinical outcomes of patients with asymptomatic AS using data from the Heart Valve Clinic International Database. Design, setting, and participants: This registry was assembled by merging data from prospectively gathered institutional databases from 10 heart valve clinics in Europe, Canada, and the United States. Asympt...
Abstract
Cited 82 times since 2018 (12.9 per year)
source: EuropePMC
European heart journal,
Volume 39, Issue 41, 1 1 2018, Pages 3715-3723
Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI).
Stocker TJ, Deseive S, Leipsic J, Hadamitzky M, Chen MY, Rubinshtein R, Heckner M, Bax JJ, Fang XM, Grove EL, Lesser J, Maurovich-Horvat P, Otton J, Shin S, Pontone G, Marques H, Chow B, Nomura CH, Tabbalat R, Schmermund A, Kang JW, Naoum C, Atkins M, Martuscelli E, Massberg S, Hausleiter J, PROTECTION VI investigators
Aims: Advances of cardiac computed tomography angiography (CTA) have been developed for dose reduction, but their efficacy in clinical practice is largely unknown. This study was designed to evaluate radiation dose exposure and utilization of dose-saving strategies for contrast-enhanced cardiac CTA in daily practice. Methods and results: Sixty one hospitals from 32 countries prospectively enrolled 4502 patients undergoing cardiac CTA during one calendar month in 2017. Computed tomography angiogr...
Abstract
Cited 3 times since 2018 (0.5 per year)
source: EuropePMC
The British journal of surgery,
Volume 105, Issue 12, 1 1 2018, Pages 1539-1540
From retribution to reconciliation after critical events in surgery.
de Vos MS, Hamming JF
Abstract
Cited 1 times since 2018 (0.2 per year)
source: EuropePMC
Journal of atrial fibrillation,
Volume 11, Issue 3, 31 5 2018, Pages 2068
Effect of Non-fluoroscopic Catheter Tracking on Radiation Exposure during Pulmonary Vein Isolation: Comparison of Four ablation systems.
Naruse Y, Keçe F, de Riva M, Watanabe M, Wijnmaalen AP, Dehnavi RA, Schalij MJ, Zeppenfeld K, Trines SA
Background: A novel non-fluoroscopic catheter tracking system (Mediguide) can be used in combination with a 3D mapping system for atrial fibrillation (AF) ablation. However, the benefit on radiation exposure of the Mediguide system compared to other ablation systems is unknown. Methods: We retrospectively enrolled consecutive 73 patients (51 men; 59±11 years; 60 paroxysmal AF) undergoing pulmonary vein isolation by the same operator. Radiation time, radiation effective dose, procedure time, AF r...
Abstract
